Agilent Technologies A

$175.21 +2.42 (1.40%)

Valuation

Market cap
48,714,512,000
Revenue TTM
$6,948,000,000
Net income TTM
$1,303,000,000
PE ratio
28.52
Forward PE
27.89
Profit margin
18.75%
Debt to equity
0.50

Trading

Volume
2,139,031
Avg volume
2,300,932
Day's range
$169.50 – $176.02
Shares out
281,929,000
Stochastic %K
93%
Beta
1.24
Analysts
Strong Sell
Price target
$175.70

Price

Company profile

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems....

Show more

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
800 227 9770
Website
https://www.agilent.com
Address
5301 Stevens Creek Boulevard, Santa Clara, United States

Latest news

Stocktwits

STRelativeStrength Sep 28, 6:50 PM
$A undiscovered breakout with 4558 watchers
0 replies
Stocktwits52wHighs Sep 28, 3:46 PM
$A printed a new 52-week high today
0 replies
FiveSigma Sep 25, 9:03 PM
$A Stock 1 / 100 [Doing a technical analysis marathon, my followers will appreciate as this is desperately needed] Agilent made a new ATH - as long as it doesn't retreat in a very bearish like manner (sharp red candlesticks down), I believe it tops around $250 - $260 early next year. Monthly RSI is going vertical. This is extremely bullish and not bearish in the slightest. I believe far OTM calls out here work best
1 replies
LewisDaKat Sep 24, 2:30 PM
$A Final Phase 2a data reinforce the profile of BIOX-101, selected for a late-breaking oral presentation at the World Stroke Congress https://marketwirenews.com/stock/a/news/final-phase-2a-data-reinforce-the-profile-of-biox-10-7699238693352481.html?utm_source=stocktwits
0 replies
Stocktwits52wHighs Sep 24, 2:16 PM
$A printed a new 52-week high today
0 replies
Orapronobis Sep 23, 8:12 PM
$A nice short scalp today…will be looking for another one …on watch … overall trend is bullish imo
0 replies
SICmunduss Sep 23, 10:22 AM
$A U.S. All Stars Conference: Agilent Technologies – Key Takeaways from the CEO & CFO interview A few points that stood out: • LC replacement cycle: still <50% through the cycle, with ~7–8 years overall. Management sees **+200–300bps** potential growth contribution. • GC:replacement cycle is earlier, around 25% through, with another ~100bps growth opportunity. • Service & consumables:~70% of service revenue is under 3-year contracts. A growing installed base should support recurring revenue and margins. • China: strong recovery across pharma, food and advanced materials. Management sees **mid/high-single-digit long-term growth. • CDMO:+30% growth in Q3. Train C comes online in spring 2027, with ~75% already booked. Train C + D could ultimately add ~$300M of revenue vs. today. • Reshoring: ~$1BN opportunity, with ~$300M targeted by 2030. Orders are now starting to come through.
0 replies
PanicSeller8 Sep 22, 2:49 PM
$A Doesn't get a lot of attention, but on a tear.
0 replies